A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner

- Sutton, Selina K., Carter, Daniel R., McArthur, Grant A., Cheung, Belamy B., Marshall, Glenn M., Kim, Patrick, Tan, Owen, Arndt, Greg M., Zhang, Xu Dong, Baell, Jonathan, Noll, Benjamin D., Wang, Shudong, Kumar, Naresh

Pharmacodynamic effects and mechanisms of resistance to Vemurafenib in patients with metastatic melanoma

- Trunzer, Kerstin, Pavlick, Anna C., Hersey, Peter, Long, Georgina V., Lawrence, Donald, Ott, Patrick A., Amaravadi, Ravi K., Lewis, Karl D., Puzanov, Igor, Lo, Roger S., Koehler, Astrid, Kockx, Mark, Schuchter, Lynn, Spleiss, Olivia, Schell-Steven, Annette, Gilbert, Houston N., Cockey, Louise, Bollag, Gideon, Lee, Richard J., Joe, Andrew K., Sosman, Jeffrey A., Ribas, Antoni, Gonzalez, Rene, McArthur, Grant A., Hutson, Thomas E., Moschos, Stergios J., Flaherty, Keith T., Kim, Kevin B., Weber, Jeffrey S.

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

- Sosman, Jeffery A., Kim, Kevin B., Hersey, Peter, Kefford, Richard, Lawrence, Donald, Puzanov, Igor, Lewis, Karl D., Amaravadi, Ravi K., Chmielowski, Bartosz, Lawrence, H. Jeffrey, Shyr, Yu, Ye, Fei, Schuchter, Lynn, Gonzalez, Rene, Pavlick, Anna C., Weber, Jeffrey S., McArthur, Grant A., Hutson, Thomas E., Moschos, Stergios J., Flaherty, Keith T.

An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development

- Cullinane, Carleen, Dorow, Donna S., Kansara, Maya, Conus, Nelly, Binns, David, Hicks, Rodney J., Ashman, Leonie Kay, McArthur, Grant A., Thomas, David M.